posaconazole stada 100 mg zarnās šķīstošās tabletes
stada arzneimittel ag, germany - posakonazols - zarnās šķīstošā tablete - 100 mg
perindopril teva 10 mg apvalkotās tabletes
teva pharma b.v., netherlands - perindoprila tosilāts - apvalkotās tabletes - 10 mg
perindopril teva 5 mg apvalkotās tabletes
teva pharma b.v., netherlands - perindoprila tosilāts - apvalkotās tabletes - 5 mg
febuxostat teva 80 mg apvalkotās tabletes
teva b.v., netherlands - febuksostats - apvalkotā tablete - 80 mg
febuxostat teva 120 mg apvalkotās tabletes
teva b.v., netherlands - febuksostats - apvalkotā tablete - 120 mg
rivaroxaban stada 15 mg apvalkotās tabletes
stada arzneimittel ag, germany - rivaroksabans - apvalkotā tablete - 15 mg
rivaroxaban stada 20 mg apvalkotās tabletes
stada arzneimittel ag, germany - rivaroksabans - apvalkotā tablete - 20 mg
rixacam 15 mg apvalkotās tabletes
adamed pharma s.a., poland - rivaroksabans - apvalkotā tablete - 15 mg
rixacam 20 mg apvalkotās tabletes
adamed pharma s.a., poland - rivaroksabans - apvalkotā tablete - 20 mg
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, švamšā šūna - antineoplastiski līdzekļi - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.